肿瘤治疗相关心血管毒性多模态评估  

Multimodal assessment of cancer therapy-related cardiovascular toxicity

作　　者：刘春丽 李潜 LIU Chunli;LI Qian(Department of Ultrasound Medicine,The Affiliated Cancer Hospital of Zhengzhou University&Henan Cancer Hospital,Zhengzhou 450003,Henan Province,China)

机构地区：[1]郑州大学附属肿瘤医院(河南省肿瘤医院)超声医学科,河南郑州450003

出　　处：《肿瘤影像学》2025年第1期11-17,共7页Oncoradiology

基　　金：河南省科技公关项目(242102310248)。

摘　　要：在当今医学领域中,肿瘤发病率日益上升,而肿瘤治疗相关心血管毒性(cancer therapy-related cardiovascular toxicity,CTR-CVT)成为一个不容忽视的关键议题,其对患者预后影响重大。随着肿瘤治疗手段的日益多样化与复杂化,诸如化疗、放疗、靶向治疗以及免疫治疗等,在为患者带来抗肿瘤希望的同时,也埋下了心血管毒性的隐患,影响治疗成效与患者的生存质量。鉴于此,对CTR-CVT进行准确且全面的评估显得尤为重要。本文从临床、心电图、影像、生物标志物等多维度评估心血管毒性,旨在为临床提供精准、实用的评估策略,以平衡肿瘤治疗效果与心脏安全性,改善患者生存质量和优化长期结局,提高患者生活质量。In the contemporary medical field,the incidence of cancer is on the rise,and cancer therapy-related cardiovascular toxicity(CTR-CVT)has become a crucial issue that cannot be overlooked,having a significant impact on the prognosis of patients.With the increasing diversification and sophistication of cancer treatment methods,including chemotherapy,radiotherapy,targeted therapy,and immunotherapy,while these offer hope for anti-tumor treatment to patients,they also carry the potential risk of cardiovascular toxicity,affecting treatment effectiveness and patients’quality of life.Therefore,it is of particular importance to accurately and comprehensively assess CTR-CVT.This article evaluated cardiovascular toxicity from multiple dimensions such as clinical manifestations,electrocardiogram,imaging,and biomarkers,aiming to provide precise and practical assessment strategies for clinical practice.These strategies are intended to balance the efficacy of cancer treatment and cardiac safety,improve patients’quality of life,optimize long-term outcomes,and enhance patients’living standards.

关 键 词：肿瘤治疗 心血管毒性 多模态 评估 

分 类 号：R541.9[医药卫生—心血管疾病] R445.1[医药卫生—内科学]